Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 9Nivolumab 5fludarabine 4Cyclophosphamide 4amatuximab 3Ipilimumab 3Fluorouracil 3Cisplatin 3tislelizumab 2spartalizumab 2budigalimab 2belinostat 2Hyperthermic Intraperitoneal Chemotherapy 2Cytoreduction Surgical Procedures 2Carboplatin 2venetoclax 1talazoparib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1atezolizumab 1aldesleukin 1Valacyclovir 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × rebastinib × Gynecologic × Clear all
NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡